Vogenx Inc Common Stock (VOGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vogenx Inc Common Stock (VOGX) has a cash flow conversion efficiency ratio of 0.250x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-350.26K) by net assets ($-1.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VOGX market cap overview for the company's overall valuation and market capitalisation.
Vogenx Inc Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Vogenx Inc Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vogenx Inc Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vogenx Inc Common Stock ranked by their cash flow conversion efficiency. See Vogenx Inc Common Stock (VOGX) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aduro Clean Technologies Inc. Common Stock
NASDAQ:ADUR
|
-0.068x |
|
Linc AB
ST:LINC
|
-0.001x |
|
Pitti Engineering Limited
NSE:PITTIENG
|
0.097x |
|
Oxford Industries Inc
NYSE:OXM
|
0.015x |
|
Beijing Succeeder Technology Inc
SHG:688338
|
0.008x |
|
Joyware Electronics Co Ltd
SHE:300270
|
-0.016x |
|
Jay Mart Public Company Limited
BK:JMART
|
0.025x |
|
BlackRock Municipal Income Closed Fund
NYSE:BFK
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Vogenx Inc Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Vogenx Inc Common Stock from 2024 to 2025. View current stock price of Vogenx Inc Common Stock for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-919.24K | $-1.11 Million | 1.210x | +126.33% |
| 2024-12-31 | $509.58K | $-2.34 Million | -4.595x | -- |
About Vogenx Inc Common Stock
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party pay… Read more